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Stereotactic Body 
Radiotherapy for 
Stage I NSCLC
The Challenge of 
Evidence-Based 
Medicine
In Response:
We thank Dr. Barlett for his 
encouraging comment on our arti-
cle.1 In the current European Society 
for Medical Oncology (ESMO)2 and 
National Comprehensive Cancer 
Network (NCCN) V 2.2013 guide-
lines, stereotactic body radiotherapy 
(SBRT) is the recommended standard 
of care for patients with stage I non–
small-cell lung cancer, who are inoper-
able because of medical comorbidities. 
Robust outcome in a multi-institu-
tional environment despite variability 
in technical details of planning and 
delivery is a prerequisite for safe and 
effective guideline-compliant SBRT 
practice on a population-based level. 
Our results therefore support two pop-
ulation-based analyses, which reported 
an improvement in overall survival for 
stage I non–small-cell lung cancer in 
the elderly patient population by the 
implementation of SBRT,3,4 providing 
high level of evidence.
Lobectomy is the accepted stan-
dard of care for operable patients. The 
achievements of high local tumor con-
trol and favorable overall survival in a 
prognostic unfavorable patient popu-
lation resulted in a transfer of SBRT 
practice to fitter, healthier patients, who 
refused surgical resection. Retrospective 
studies described outcome approaching 
surgical results, indicating that overall 
survival after SBRT is mainly com-
promised by age and comorbidities of 
the patients and not by inferior onco-
logical efficacy compared with surgi-
cal resection.5,6 On the basis of these 
To the Editor:
I am writing with regard to 
Guckenberger et al.’s1 article relating 
the safety and efficacy of stereotactic 
body radiotherapy (SBR) for stage 1 
non–small-cell lung cancer in routine 
clinical practice.
I agree this is an important 
therapy that requires continual 
review to elucidate optimal therapeu-
tic delivery for efficacy and safety 
concerns and am encouraged by the 
consistency reported by other studies 
of the overall 3-year survival of 48% 
patients.2
There is temptation to compare 
SBR with surgery in the potentially 
fit patient. A recent review of the 
U.K. experience in surgical resec-
tion of lung cancer by Powell et al.3 
may provide a robust comparison of 
the safety of the surgical alternative 
which in no cohort, other than racial, 
achieved a safety equivalent to SBR. 
The cohort of stage 1A NSCLC 
patients had 30- and 90-day mortal-
ity rate at 1.6% and 3.4%, respec-
tively. This is significantly worse 
than SBR, despite being an intrinsi-
cally fitter population by virtue of 
being offered surgery. Is it time to 
usurp the surgeon?
Overall survival is the last 
remaining issue to determine whether 
SBR has a broader role. Alexander 
et al.4 have attempted to compare 
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SABR with surgery in elderly patients, 
however, their study was limited by a 
lack of age matching of the cohort 
and the use of sublobar resections. An 
important, age-matched retrospective 
review by Varlotto et al.5 suggests 
little difference in efficacy of surgery 
or SBR.
With the technical insights 
garnered from Guckenberger et al.’s 
review1 we are at clinical equipoise 
and await results of current, pro-
spective randomized trials free of 
selection bias. In the interim, which 
is likely to be prolonged, a frank 
and open discussion of the options 
with patients is required. At the 
very least, the former apathy toward 
management of elderly patients 
with early-stage lung cancer must 
be revoked in light of a safe, eff ica-
cious, and low-burden therapy such 
as SBR seems to be.
James Bartlett, MBBS
Western Hospital
Melbourne, Australia 
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experiences, three randomized-con-
trolled trials (ROSEL, STAR, RTOG 
1021) have been started, all comparing 
SBRT with surgery, either lobectomy or 
sublobar resection. However, all three 
trials closed early because of very poor 
accrual of patients. Was all the effort 
of these randomized trials for nothing? 
Certainly no! From a technical perspec-
tive, these trials achieved highly valu-
able standardization, quality-assurance, 
and credentialing procedures for imple-
mentation and practice of SBRT.7,8 
From a clinical perspective, these tri-
als engaged multidisciplinary discus-
sion and interaction aiming at the best 
treatment approach for each individual 
patient.
Propensity-score matching is 
a statistical tool, which attempts to 
account for confounding covariates 
and thereby simulates a randomized 
trial based on retrospectively acquired 
data. Several such comparisons have 
been performed and all concluded that 
SBRT is at least as effective as sublobar 
resection and comparable with lobec-
tomy.4,9–11 This conclusion seems robust 
with reproducible results in these differ-
ent studies. Nevertheless, only known 
and available confounding covariates 
were statistically corrected, which 
leaves uncertainties behind.
How to proceed now that 
 level-one evidence will not be available 
for comparison of SBRT and surgical 
resection? In daily clinical practice, 
patients should not only be discussed 
but be informed by a multidisciplinary 
team about the available (or lack of) evi-
dence, the surgical and SBRT options, 
and their specific pros and cons. This 
is especially true for the elderly and 
comorbid patient population as stated 
by Dr. Barlett but the encouraging 
outcome of SBRT might increase the 
number of younger and fitter patients 
actively refusing surgery and opting 
for SBRT: we should prepare ourselves 
with the establishment of prospective 
databases for future generation of the 
highest data quality and evidence possi-
ble in the absence of randomized trials.
Matthias Guckenberger, MD
Department of Radiation Oncology
University of Würzburg
Würzburg, Germany 
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To the Editor:
In their report, Sholl et al.1 elegantly 
demonstrate strong association between 
anaplastic lymphoma kinase immunohis-
tochemistry (ALK IHC) and ALK fluo-
rescence in situ hybridization (FISH) for 
detecting ALK rearrangements in lung 
adenocarcinoma. Using the clone 5A4 
the authors observed that ALK IHC was 
93% sensitive and 100% specific when 
compared with ALK FISH. We agree with 
their conclusion that a combined FISH 
and IHC approach enhances chances to 
identify ALK rearrangements in non–
small-cell lung cancer.
However, we would like to com-
ment on their interpretation of a FISH 
result considered as false positive.
In case 2, ALK FISH reveals tumor 
nuclei showing multiple fused signals (>2) 
associated with a single green signal (Fig. 
2).1 The authors interpret this profile as an 
atypical ALK rearrangement, arguing for 
an asymmetric splitting of the green probe 
(5′ centromeric) consisting of a single 
 bright-green signal in addition to a small 
green signal fused to a red signal.
But the ALK breakpoint is known to 
be constant.2 This molecular feature justi-
fies the use of the Vysis ALK Break Apart 
FISH Probe Kit with a green probe (5’ 
centromeric) and a red probe (3′ telomeric, 
complementary to the ALK tyrosine kinase 
domain) surrounding the ALK breakpoint. 
ALK rearrangement leads to an increased 
distance between the green signal (5′) 
and the red signal (3′). Single red signals 
(3′), without corresponding green signals, 
because of a deletion of 5′ end of ALK, 
